immutep (asx:imm, nasdaq:immp) discusses a transformative year for lag-3 therapies
Published 1 year ago • 207 plays • Length 6:25Download video MP4
Download video MP3
Similar videos
-
4:44
immutep (asx:imm, nasdaq:immp) - innovative cancer therapies
-
15:49
immutep (asx:imm) - webinar presentation
-
6:03
immutep (asx:imm, nasdaq:immp) reports positive discussions with the fda and strong survival data
-
4:40
immutep (asx:imm, nasdaq:immp) announces encouraging trial data for lung cancer therapy
-
7:58
immutep : immutep’s leading position within the lag-3 competitive landscape, 04 may 2021
-
4:32
immutep limited (asx:imm; nasdaq:immp) ceo and executive director marc voigt provides company update
-
11:47
what is stage iii melanoma?
-
23:49
dr andrew ilchyshyn - multiple melanoma
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
1:18
melanoma metastases to ovary
-
9:00
when do i need therapy for my stage ii or stage iii melanoma?
-
1:10
ask unmc! what is melanoma and how do i know if i'm at risk?
-
3:15
is aml susceptible to immunotherapy?
-
0:52
all melanomas are not the same
-
8:24
management of side effects for braf/mek inhibitors for melanoma
-
3:22
clinical activity of fianlimab, an anti-lag-3 mab combined with cemiplimab in advanced melanoma
-
0:35
mutlilab 2 lhs img
-
1:05:54
melanoma care: continued progress with immunotherapy in resectable and unresectable disease
-
25:44
the latest treatments for melanoma - an overview
-
25:41
new immunotherapies, precision medicine and biomarkers in melanoma
-
13:17
do i need more treatment after surgery?